Dovato, a combination HIV medication, received FDA approval on February 4, 2020 [1]. It is manufactured by ViiV Healthcare [2].
What is Dovato used for?
Dovato is a complete treatment regimen for HIV-1 infection in adults and pediatric patients weighing at least 143 pounds (65 kg) who have no known or suspected viral resistance to either of its components, dolutegravir or lamivudine [1].
What are the active ingredients in Dovoto?
Dovoto combines dolutegravir and lamivudine in a single tablet [1]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) [1].
How does Dovoto work?
Dolutegravir inhibits the integrase enzyme, preventing the integration of proviral DNA into the host cell genome. Lamivudine acts as a competitive inhibitor of HIV-1 reverse transcriptase, blocking the conversion of viral RNA into DNA [1].
When does Dovoto's patent expire?
Information on specific patent expiry dates for Dovoto is available through resources like DrugPatentWatch.com [3].
What are the potential side effects of Dovoto?
Common side effects reported with Dovoto include upper respiratory tract infections, headache, and diarrhea [1]. Serious side effects can include hypersensitivity reactions and liver enzyme elevations, particularly in patients with underlying liver disease [1].
How does Dovoto compare to other HIV treatment options?
Dovoto offers a complete HIV treatment in a single tablet containing two drugs, which may appeal to patients seeking simplified regimens [1]. Other HIV treatment options include single-drug therapies, multi-drug regimens with more than two active ingredients, and various combinations of different drug classes [4]. The choice of treatment depends on individual patient factors, including viral resistance, comorbidities, and potential drug interactions [4].